Miracor Medical Announces FDA IDE Approval For PiCSO® Pivotal Study
Miracor Medical SA (Miracor Medical) has announced the approval of an Investigational Device Exemption (IDE) from the FDA, enabling the company to initiate a pivotal study with its Pressure-controlled intermittent Coronary Sinus Occlusion (PiCSO) technology. The PiCSO-AMI-II multicenter, randomized trial will enroll 300 patients with anterior ST-segment Elevation Myocardial Infarction (STEMI) presenting with TIMI flow 0, 1, and 2 within 12 hours of symptom onset. The primary efficacy endpoint of the study will be infarct size measured by cardiac magnetic resonance imaging (CMR) at 5 days. The primary safety endpoint is a performance goal for device and procedure related adverse events at 30 days. Major adverse cardiac events and heart failure endpoints will be captured acutely and for up to 3 years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220823005069/en/
PiCSO® Impulse Catheter (Photo: Business Wire)
PiCSO-AMI-II will be the second major randomized trial to evaluate the role of PiCSO in improving coronary microvascular function and reducing infarct size in patients presenting with anterior STEMI. Miracor is currently recruiting 144 patients in PiCSO-AMI-I, a landmark European randomized controlled trial, with comparable endpoints as the approved US trial. Recruitment in the European study is expected to end this summer. It is anticipated that a future patient-level pooled meta-analysis of the two studies will demonstrate a hard clinical endpoint improvement in heart failure hospitalization.
PiCSO is used as an adjunctive procedure after epicardial flow has been restored during the primary percutaneous coronary intervention (PCI) procedure. The unique mechanism of action, of intermittently occluding the coronary sinus outflow, redistributes venous blood-flow to the peri-infarct zone and enhances the coronary microcirculation viability by washing-out debris and other noxious agents of the infarct process. Early non-randomized European studies have suggested that this leads to reduced incidence of coronary microvascular obstruction (MVO) [3,4] and smaller infarct size, which are both strongly correlated to improvement in heart failure hospitalizations and reduced mortality following primary PCI . Despite improvements in patient care pathways, widespread use of reperfusion strategies, and adjuvant pharmacological therapies, the one-year mortality rate after STEMI in high-risk patients has plateaued over the past decade at 14% . Also, heart failure development after hospital discharge is very prevalent, being diagnosed in approximately 13% of patients at 30 days and 20–30% at 1 year after discharge .
“Reducing infarct size and MVO is a key factor in improving survival and reducing the risk of heart failure among patients with heart attack. PiCSO therapy is a promising new therapy to reduce infarct size and improve outcomes in anterior STEMI patients. The FDA-approved randomized IDE trial has been designed to validate the safety and effectiveness of PiCSO.” said Prof. Gregg W. Stone, (Director of Academic Affairs for the Mount Sinai Heart Health System, New York, NY, USA) who will be study principal investigator, with Prof. Marco Valgimigli of Istituto Cardiocentro Ticino in Lugano, Switzerland, as the study co-principal investigator.
“In addition to the ICD-10-PCS code that was granted by the Centers for Medicare and Medicaid Services (CMS) in April 2022, the Investigational Device Exemption marks a key milestone in the company’s lifecycle and speaks to the positive evolution of the company. We look forward to conducting a meticulous study with our clinical investigators to bring PiCSO to American patients.” said Olivier Delporte, CEO. The company plans to raise funds later this year to execute this important study, support company operations and assess potential partnerships for Asia.
The PiCSO Impulse System received ‘Breakthrough Designation’ from the FDA in 2019 and the CE-Mark in 2020. The development of Miracor’s PiCSO technology is supported by a reimbursable cash advance from the Walloon Region since August 2017.
About Miracor Medical
Miracor Medical (www.miracormedical.com), located in Awans, Belgium, provides innovative solutions for the treatment of severe cardiac diseases, aiming to improve short and long-term clinical outcomes and reduce associated cost.
Miracor Medical was originally founded by a cardiac surgeon at the Medical University of Vienna, Austria, Professor emeritus Werner Mohl. Prof. Mohl has worked and published about coronary sinus occlusion and interventions for decades, and invented the PiCSO therapy concept. Miracor Medical has developed the PiCSO Impulse System, the first and only coronary sinus intervention designed to reduce infarct size, improve cardiac function by clearing microcirculation and potentially reduce the onset of heart failure following acute myocardial infarction.
# # # # #
NOTE: The PiCSO® Impulse System is limited to investigational use in the United States.
- Szummer, K., et al., Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995–2014. European Heart Journal, 2017. 38(41): p. 3056-3065.
- Jenča, D., et al., Heart failure after myocardial infarction: incidence and predictors. ESC Heart Failure, 2021. 8(1): p. 222-237
- Egred, M., et al., Effect of Pressure-controlled intermittent Coronary Sinus Occlusion (PiCSO) on infarct size in anterior STEMI: PiCSO in ACS study. IJC Heart & Vasculature, 2020. 28: p. 100526.
- De Maria et al. Index of microcirculatory resistance-guided therapy with pressure-controlled intermittent coronary sinus occlusion improves coronary microvascular function and reduces infarct size in patients with ST-elevation myocardial infarction: the Oxford Acute Myocardial Infarction - Pressure-controlled Intermittent Coronary Sinus Occlusion study (OxAMI-PICSO study). EuroIntervention 2018;14(3):e352-e359.
- Stone et al. Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials. J Am Coll Cardiol. 2016 Apr 12, 67(14), 1674-1683.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Miracor Medical SA
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mercans Adds Industry Veteran Steve Goldberg to its Board4.10.2022 17:07:00 EEST | Press release
Mercans, the global payroll technology leader, has announced that Steve Goldberg has joined its board as a non-executive director. The addition of an industry veteran to Mercans’ board follows several recently announced corporate governance changes to strengthen the board and executive management team of the global payroll and EOR service provider. When announcing Steve Goldberg’s appointment, Mercans’ board said, “We welcome Steve as a non-executive director to the board and believe that his long-term industry experience and insights will bring unique perspectives to Mercans. Steve’s strategic vision for the global payroll and HCM industry aligns well with Mercans’ strategy. We are confident that his leadership will further accelerate Mercans’ growth and strengthen its ability to deliver award-winning global payroll technology.” Steve Goldberg's 30+ year career on all sides of HR and Payroll technology includes HR executive roles across 3 continents, serving as HCM product strategy le
Announcing ClickHouse Cloud: Democratizing lightning-fast insights and analytics4.10.2022 17:00:00 EEST | Press release
Today, ClickHouse, Inc. announced the launch of ClickHouse Cloud, a lightning-fast cloud-based database that simplifies and accelerates insights and analytics for modern digital enterprises. With no infrastructure to manage, ClickHouse Cloud architecture decouples storage and compute and scales automatically to accommodate modern workloads, so users do not have to size and tune their clusters to achieve blazing-fast query speeds. Historically, data infrastructure and analytics solutions have been expensive and difficult to manage. Companies frequently bore the expense of specialized experts and infrastructure teams, only to receive unacceptable performance in return, as legacy solutions struggled to scale. The introduction of ClickHouse Cloud, built by the creators of the much-loved open source project, brings enterprise-grade data analytics and lightning-fast insights to the masses. A ClickHouse Cloud user can log in and launch a new service with a few clicks, and start analyzing thei
GlobalLogic Inaugurates Two New Engineering Centers in Mexico4.10.2022 16:00:00 EEST | Press release
GlobalLogic Inc., a Hitachi Group company and Digital Engineering leader, today announced the opening of two new engineering and sales centers in Mexico. The centers will be located at Guadalajara and Mexico City. The expansion will help GlobalLogic meet the robust demand for digital solutions, as companies across industries and around the globe continue to transform their products and digital experiences to better engage their customers, access new revenue streams, and make their offerings more sustainable. The sites expand on GlobalLogic’s existing Latin American presence, which includes engineering and sales centers in Argentina and Chile. “We have executed on a steady expansion campaign for years, identifying gaps in the market and pairing those with emerging customer hubs,” said Vishal Anand, Group Vice President & Head of Americas, GlobalLogic. “The LatAm region is a critical component of that growth strategy as our clients look to offer differentiated products and services along
Expensify Gives Accountants a Chance to Win Their Spot at ExpensiCon in Italy4.10.2022 16:00:00 EEST | Press release
Expensify, Inc. (Nasdaq: EXFY), a payments superapp that helps individuals and businesses around the world simplify the way they manage money across expenses, corporate cards and bills, today announced the “Win your spot at ExpensiCon” contest. The contest is open to any accountant, but only five accountants will win a spot at this exclusive, invite-only conference for themselves and a guest. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221004005072/en/ “We’re bringing together 100 of the industry’s best and brightest, and five of the most coveted spots in accounting are now available to any accountant from any size firm,” says David Barrett, founder and CEO of Expensify. “This is an unparalleled opportunity to join a global community of accounting leaders with hundreds of years of combined experience to plan for the next generation of the profession. Together, we can identify and solve the most complex challenges that wil
INNIO‘s next generation Jenbacher 3F engine offers significantly higher efficiency4.10.2022 15:07:00 EEST | Press release
INNIO announced today that it has launched its next generation Jenbacher Type 3F engine. This forms part of INNIO’s commitment to empower the transition to net zero with flexible, scalable, and resilient energy solutions and services. The new and improved Jenbacher Type 3F engine offers customers proven robustness and reliability while delivering up to two percentage points of efficiency boost, the engine line’s highest efficiency ever. In addition to delivering efficiency as high as 43.3% when operating on pipeline gas, the Type 3F engine is optimized for reduced total hydrocarbon (THC) emissions, future-proofed fuel flexibility, and enhanced serviceability. Moreover, the latest 3F technology is offered with a “Ready for H2” option and retrofittable for most of the installed Type 3 fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221004005681/en/ INNIO's next generation Jenbacher Type 3F engine has the line's highest e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom